This site is intended for healthcare professionals

Dapagliflozin can lower hospitalizations in kidney patients

Time : 8th of December 2022 12:07:15 PM Nephrology,Endocrinology & Diabetes

Patients with chronic kidney disease with or without type 2 diabetes and with a urinary albumin-creatinine ratio of 200 to 5,000 mg/g, eGFR of 25 to 75 mL/min/1.73 m2 were treated with dapagliflozin or placebo in a study. The drug reduces the chances of hospitalization in these patients compared to a placebo. This benefit was seen regardless of the presence of diabetes.
  Physician's Weekly

Conservative management for CKD could lower hospitalization risk

Time : 6th of December 2022 12:54:29 PM Physician/Medicine,Nephrology

Patients with chronic kidney disease who opted for conservative management had lower rates of hospitalization compared to that in people who opted for dialysis, as per a study. Congestive failure, hypertension-related problems, and respiratory illnesses were common reasons for hospitalization among patients in both dialysis and conservative management groups.

Empagliflozin can reduce the progression of kidney disease

Time : 28th of November 2022 11:25:11 AM Nephrology,Cardiology

Patients with chronic kidney disease were randomized to the drug or placebo in a study. Fewer patients in the drug group had progressed kidney disease or died due to cardiovascular causes than in the placebo group (13.1% vs 16.9%). These findings were consistent among participants with or without diabetes. The hospitalization risk was also lower in the drug group.
  Twitter @AmitGoyalMD

FDA alerts about hypocalcemia risk with denosumab

Time : 23rd of November 2022 12:28:09 PM Pharma News,Nephrology

The agency's review showed that the osteoporosis drug denosumab used in kidney patients on dialysis could increase the risk of hypocalcemia. An internal investigation also linked the drug with a considerable risk of hospitalization and death. FDA suggested patients not stop taking the drug without consulting their doctor as it could worsen their osteoporosis.

How to differentiate between kidney stones and gallbladder stones?

Time : 18th of November 2022 10:59:46 AM Nephrology,Gastroenterology,Entertainment

Gallstones and kidney stones can exist without symptoms. Gallstones occur in the gallbladder, a part of the digestive system, while kidney stones occur in the urinary tract. Gallstones cause pain in the mid-upper abdomen and spread to the back or below the right shoulder. Kidney stones cause pain in the side or lower back, which spreads to the groin and lower abdomen.
  Twitter @ClevelandClinic

Renal denervation trial for hypertension does not meet its primary endpoint

Time : 17th of November 2022 11:27:49 AM Physician/Medicine,Nephrology,Cardiology

The SPYRAL HTN-ON MED clinical trial failed to meet its goal of reducing blood pressure with renal denervation compared to a sham procedure in people taking antihypertensive drugs, as per a study. The denervation procedure caused a 6.5 mmHg reduction compared to 4.5 mmHg with the sham procedure, with only a 51% probability of denervation being superior.

Dialysis not the best option for some patients with advanced kidney disease

Time : 15th of November 2022 10:26:44 AM Physician/Medicine,Nephrology

A study revealed that patients who got dialysis for advanced kidney disease had a higher risk of hospitalization than those receiving more palliative care. Patients who received dialysis early when they had higher levels of renal function had the highest hospitalization rates than those who received dialysis at lower levels of function and those on conservative treatment.

Oral budesonide could treat IgA nephropathy

Time : 27th of October 2022 10:03:42 AM Nephrology

Patients with IgAN treated with Nefecon (oral budesonide) had a 27% lower 24-hour urine protein-to-creatinine ratio at 9 months compared to those treated with a placebo, as per a phase 3 study. Also, they experienced the benefit of eGFR preservation. The treatment was well-tolerated and adverse events were primarily reversible and mild to moderate in severity.
  Twitter @ASPNeph

Experts recommend a name change for diabetes insipidus

Time : 26th of October 2022 12:47:53 PM Physician/Medicine,Nursing,Nephrology,Endocrinology & Diabetes,Diagnostics & Pathology

The name change aims to avoid confusion with diabetes mellitus and bad outcomes and experiences for patients, especially those cared for by non-endocrine specialists. Arginine vasopressin deficiency is proposed for central etiologies, while arginine vasopressin resistance is for nephrogenic etiologies. About 85% of patients in a survey said they preferred the change.

FDA approves a self-administered, subcutaneous loop diuretic furosemide

Time : 13th of October 2022 09:44:43 AM Physician/Medicine,Pharma News,Nephrology,Cardiology

FUROSCIX (furosemide injection) is developed using a SmartDose On-Body Drug Delivery technology for self-administration by a patient or caregiver at home. It can be used for treating congestion from fluid overload in adults with chronic heart failure. However, it cannot be used in emergency situations or for individuals suffering from acute pulmonary edema.